Literature DB >> 11265163

In vitro susceptibility of 137 Candida sp. isolates from HIV positive patients to several antifungal drugs.

S Magaldi1, S Mata, C Hartung, G Verde, L Deibis, Y Roldán, C Marcano.   

Abstract

Oropharyngeal candidiasis caused by various species of Candida is one of the most common infections in HIV seropositive or AIDS patients. Drug resistance among these yeasts is an increasing problem. We studied the frequency of resistance profile to fluconazole, itraconazole, ketoconazole, amphotericin B and terbinafine of 137 isolates of Candida sp. From HIV positive or AIDS patients with oropharyngeal candidiasis at Instituto de Inmunología, U.C.V. and the Hospital "Jose Ignacio Baldó", Caracas Venezuela, using the well diffusion susceptibility test (Magaldi et al.). We found that nearly 10% of C. albicans isolates were primarily fluconazole resistant, 45% of C. albicans isolates from patients with previous treatment were resistant to fluconazole, of which 93% showed cross-resistance to itraconazole, and even about 30% of C. tropicalis (n = 13) were resistant to fluconazole and/or itraconazole. To this respect, several recent reports have been described antifungal cross-resistance among azoles. Therefore, we consider that C. tropicalis should be added to the growing list of yeast in which antifungal drug resistance is common. This report could be useful for therapeutic aspect in AIDS patients with oral candidiasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11265163     DOI: 10.1023/a:1007237711099

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   3.785


  21 in total

1.  Mucosal candidiasis caused by non-albicans species of Candida in HIV-positive patients.

Authors:  W G Powderly
Journal:  AIDS       Date:  1992-06       Impact factor: 4.177

2.  Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole.

Authors:  M Akova; H E Akalin; O Uzun; D Gür
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-07       Impact factor: 3.267

Review 3.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients.

Authors:  A Vuffray; C Durussel; P Boerlin; F Boerlin-Petzold; J Bille; M P Glauser; J P Chave
Journal:  AIDS       Date:  1994-05       Impact factor: 4.177

5.  Cross-sectional study of oral Candida carriage in a human immunodeficiency virus (HIV)-seropositive population: predisposing factors, epidemiology and antifungal susceptibility.

Authors:  A G Schoofs; F C Odds; R Colebunders; M Ieven; H Goossens
Journal:  Mycoses       Date:  1998 May-Jun       Impact factor: 4.377

6.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

7.  Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients.

Authors:  S G Revankar; W R Kirkpatrick; R K McAtee; O P Dib; A W Fothergill; S W Redding; M G Rinaldi; T F Patterson
Journal:  J Infect Dis       Date:  1996-10       Impact factor: 5.226

8.  In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

Authors:  F Barchiesi; A L Colombo; D A McGough; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

9.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

10.  Oral candidiasis and immune status of HIV-infected patients.

Authors:  H Nielsen; K D Bentsen; L Højtved; E H Willemoes; F Scheutz; M Schiødt; K Stoltze; J J Pindborg
Journal:  J Oral Pathol Med       Date:  1994-03       Impact factor: 4.253

View more
  8 in total

1.  Detection of Candida dubliniensis in Venezuela.

Authors:  Claudia Hartung de Capriles; Sofía Mata-Essayag; Celina Pérez; Maria Teresa Colella; Arantza Roselló; Carolina Olaizola; Sylvia Magaldi Teresa Abate
Journal:  Mycopathologia       Date:  2005-10       Impact factor: 2.574

2.  "In vitro" antifungal activity of protease inhibitors.

Authors:  S Mata-Essayag; S Magaldi; C Hartung de Capriles; L Deibis; G Verde; C Perez
Journal:  Mycopathologia       Date:  2001       Impact factor: 2.574

3.  Antifungal Resistance of Candida Species Isolated from HIV Patients in a Tertiary Care Hospital, Mysuru, Karnataka.

Authors:  Umamaheshwari Shivaswamy; M N Sumana
Journal:  Indian J Dermatol       Date:  2020 Sep-Oct       Impact factor: 1.494

4.  Pseudomembranous candidiasis in HIV/AIDS patients in Cali, Colombia.

Authors:  Luz Ángela Castro; María Inés Álvarez; Ernesto Martínez
Journal:  Mycopathologia       Date:  2012-10-21       Impact factor: 2.574

Review 5.  Oral manifestations in the era of HAART.

Authors:  Gail Cherry-Peppers; Christine O Daniels; Valli Meeks; Charles F Sanders; David Reznik
Journal:  J Natl Med Assoc       Date:  2003-02       Impact factor: 1.798

6.  Update on terbinafine with a focus on dermatophytoses.

Authors:  Jason G Newland; Susan M Abdel-Rahman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-21

7.  Spectrum and the In Vitro Antifungal Susceptibility Pattern of Yeast Isolates in Ethiopian HIV Patients with Oropharyngeal Candidiasis.

Authors:  Birhan Moges; Adane Bitew; Aster Shewaamare
Journal:  Int J Microbiol       Date:  2016-01-05

8.  A representative of arylcyanomethylenequinone oximes effectively inhibits growth and formation of hyphae in Candida albicans and influences the activity of protein kinases in vitro.

Authors:  Maciej Masłyk; Monika Janeczko; Oleg M Demchuk; Anna Boguszewska-Czubara; Hieronim Golczyk; Anna Sierosławska; Anna Rymuszka; Aleksandra Martyna; Konrad Kubiński
Journal:  Saudi Pharm J       Date:  2017-12-05       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.